Twin Tree Management’s Sarepta Therapeutics SRPT Stock Holding History

Twin Tree Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-64,900	Closed	-$7.89M	–	1906
2024 Q4	$7.89M	Sell	64,900 -150,800	-70%	-$18.5M	0.01%	781
2024 Q3	$26.9M	Buy	215,700 +113,000	+110%	+$15.6M	0.05%	326
2024 Q2	$16.2M	Buy	+102,700	New	+$13.2M	0.04%	432
2024 Q1	–	Sell	-21,000	Closed	-$2.03M	–	1588
2023 Q4	$2.03M	Buy	+21,000	New	+$2.01M	﹤0.01%	1056
2020 Q2	–	Sell	-102,100	Closed	-$9.99M	–	1689
2020 Q1	$9.99M	Buy	+102,100	New	+$11.7M	0.05%	328
2019 Q4	–	Sell	-114,000	Closed	-$8.59M	–	1459
2019 Q3	$8.59M	Buy	+114,000	New	+$13.5M	0.03%	359

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Twin Tree Management's SRPT Position: Q1 2025 in Review

Twin Tree Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 61,658 shares — an estimated $7.5M sold.

Twin Tree Management first reported a position in SRPT in Q3 2019 and held it in 6 quarters. The position peaked at $13.4M in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Twin Tree Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Twin Tree Management sold 61,658 Sarepta Therapeutics shares in Q1 2025, an estimated $7.5M.
Twin Tree Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 6 quarters.
Twin Tree Management's Sarepta Therapeutics position peaked at $13.4M in Q3 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Twin Tree Management's 13F filing for Q1 2025, filed 15 May 2025.